Market research
OBD.LSE Oxford BioDynamics Plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- Not available
- Beta
- -0.15
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- GB00BD5H8572
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- Not available
- Beta
- -0.15
About
About Oxford BioDynamics Plc
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OBD.LSE discussion.
5 years, 4 months ago
Oxford BioDynamics Plc is currently in a long term downtrend where the price is trading 24.0% below its 200 day moving average.
From a valuation standpoint, the stock is 55.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 196.5.
Oxford BioDynamics Plc's total revenue sank by 0.0% to $166K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-760K since the same quarter in the previous year.
Finally, its free cash flow fell by 29.2% to $-1M since the same quarter in the previous year.
Based on the above factors, Oxford BioDynamics Plc gets an overall score of 1/5.